Article Text

PDF
Unclassified Variants of BRCA1 and BRCA2 in Korean Patients With Ovarian Cancer
  1. Min Chul Choi, MD*,,
  2. Ja-Hyun Jang, MD, PhD,
  3. Sang Geun Jung, MD, PhD,
  4. Hyun Park, MD, PhD,
  5. Won Duk Joo, MD, PhD,
  6. Seung Hun Song, MD, PhD,
  7. Chan Lee, MD, PhD and
  8. Je Ho Lee, MD, PhD*,
  1. *Hereditary Gynecologic Cancer Clinic, Precision Medicine Center,
  2. Comprehensive Gynecologic Cancer Center, Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do; and
  3. Green Cross Laboratories, Yongin City, Republic of Korea.
  1. Address correspondence and reprint requests to: Je Ho Lee, MD, PhD, CHA Bundang Medical Center, Yatap-dong, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-712, Republic of Korea. E-mail: jeholee@cha.ac.kr; or Min Chul Choi, MD, CHA Bundang Medical Center, Yatap-dong, Bundang-gu, Seongnam-si, Gyeonggi-do 463-712, Republic of Korea. E-mail: oursk79@cha.ac.kr.

Abstract

Objective The aim of the present study was to investigate unclassified variants (UVs) in BRCA1 and 2 of Korean patients with ovarian cancer.

Methods We retrospectively analyzed 138 patients diagnosed with ovarian/fallopian tubal/peritoneal cancer between January 2013 and January 2016, whose BRCA genetic test results and clinical characteristics were available for review. Patient peripheral blood lymphocyte specimens were assessed for BRCA mutations and variations by direct sequencing. Identified UVs were classified according to several algorithms.

Results The results of genetic testing revealed 31 (22.5%, 31/138) pathogenic BRCA mutations (24 BRCA1, 7 BRCA2 mutations). The BRCA1 c.390C>A mutation was observed in 4 patients (12.9%, 4/31). Thirty-four (24.6%, 34/138) BRCA UVs were identified in 33 patients. Of these, the BRCA1 c.4883T>C and BRCA2 c.8187G>T variants were each detected in 4 patients (4/34, 11.8%). According to the used algorithms and cosegregation test, the BRCA1 c.5339T>C and BRCA2 c.8437_8439delGGA variants were both predicted to be likely pathogenic.

Conclusions The 2 identified likely pathogenic UVs require further verification with clinical evidence. Clarifying the clinical significance of UVs is an increasingly important step for cancer treatment in the current era of precision medicine.

  • BRCA mutation
  • Ovarian neoplasms
  • Unclassified variants
  • Variants of unknown significance

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflict of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.